Nkarta Therapeutics Inc. (NASDAQ: NKTX) will move to an 88,000-square-foot facility that will not only serve as a new headquarters, but will also serve for the research, progression and long-term advertising production of its mobile treatment line.
The Corporation revealed the charge of the project.
The facility will be a multi-product production and is expected to go live until the end of 2023, Nkarta said.
At full capacity, the facility is expected to produce an advertisement for several mobile treatment products.
The biotechnology is lately in Phase 1 trials for its treatment, NKX101, which uses NK cells from healthy donors designed to exploit a chimeric antigenic receptor targeting the NKG2D ligand in certain blood cancers.
The new headquarters will add to a smaller 2700-square-foot facility, also in the San Francisco area, which Nkarta has completed.
At its smallest site, the Company is generating materials from some other remedy known as NKX019, an experimental mobile NK cure designed to target tumors expressing CD19 antigen for the remedy of mobile B malignant tumors.
The Company expects phase 1 studies to begin at this time of year.
In May, Nkarta collaborated with CRISPR Therapeutics to co-develop and commercialize two CAR-NK CD70 treatments primarily for cancer indications.
Price action: NKTX shares closed at $28. 28 on Tuesday.
See about Benzinga
Click here to view Benzinga’s transactions
Sesen Bio Announces Positive Results from FDA End-of-Cycle Meeting for Vicineum Application
BriaCell’s Combined Early Stage Complex Breast Cancer Initiates Recruitment
© 2021 Benzinga. com. Benzinga offers investment advice All rights reserved.